Literature DB >> 29490182

Friction in the Path to Use of Biosimilar Drugs.

Richard G Frank1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29490182     DOI： 10.1056/NEJMp1714908

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Authors:  Brian K Chen; Y Tony Yang; Charles L Bennett
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?

Authors:  Stanton R Mehr; Richard A Brook
Journal:  Pharmaceut Med       Date:  2019-02

3.  Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.

Authors:  Mariana P Socal; Kelly E Anderson; Aditi Sen; Ge Bai; Gerard F Anderson
Journal:  Value Health       Date:  2020-02-17       Impact factor: 5.725

4.  Biologicals and Biosimilars in Hematology: The Case of Rituximab.

Authors:  Arnold G Vulto
Journal:  Hemasphere       Date:  2019-11-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.